European Lithium Ltd - Issue of Securities
RNS Number : 2869P
European Lithium Limited
08 June 2020
 

European Lithium Ltd

("European Lithium", "EUR" or "the Company")

ISSUE OF SECURITIES

European Lithium Limited (ASX:EUR, FRA:PF8, VSE:ELI, NEX:EUR) (the Company) advises that 9,166,666 fully paid shares (the Shares) have been issued. 

 

In respect to the Shares, a total of 5,454,544 have been issued to Winance as announced on 5 March 2020. The full announcement can be seen at:

https://www.asx.com.au/asxpdf/20200305/pdf/44fs6q67t8lgms.pdf

 

The balance of 3,712,122 shares have been issued in relation to the Company's announucement of 27th May 2020 to convert $118,182 of debt into equity. 

 

Application has been made for 9,166,666 shares to be admitted to trading on Aquis (Admission). Admission is expected to occur at 8:00am on or around 12 th  June 2020. Following Admission, the Company's issued share capital will comprise 662,293,209 ordinary shares of no par value, with each share carrying the right to one vote. The Company does not hold any ordinary shares in treasury.  The above figure of 662,293,209 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or of a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

Tony Sage
Non-Executive Chairman
European Lithium Limited

- END -

 

 

Visit the Company's website (www.europeanlithium.com) to find out more about the advanced Wolfsberg Lithium Project located in Austria.

For further information please contact:

European Lithium Ltd

+61 861 819 792

Tony Sage

ir@europeanlithium.com

 

NEX Corporate Adviser

+44 207 220 1666

James Joyce


James Sinclair-Ford


 


This information is provided by RNS, the news service of the . RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NEXFPMBTMTTMBRM ]]>